These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 10604960)

  • 1. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
    Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
    J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
    J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of the novel highly potent diuretic 7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinone 4-oxime-O-sulfonic acid potassium salt.
    Shinkawa T; Yamasaki F; Kikuchi A; Nakakuki M; Nishijima K; Uemura A; Mizota M; Orita Y
    Arzneimittelforschung; 1992 Dec; 42(12):1466-72. PubMed ID: 1337698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
    Kazama I; Arata T; Michimata M; Hatano R; Suzuki M; Miyama N; Sanada S; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
    Nephrol Dial Transplant; 2007 Jan; 22(1):68-76. PubMed ID: 16702208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans.
    Shimizu K
    Clin Nephrol; 2003 Mar; 59(3):164-73. PubMed ID: 12653258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
    Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diuretic activity and kidney medulla AQP1, AQP2, AQP3, V2R expression of the aqueous extract of sclerotia of Polyporus umbellatus FRIES in normal rats.
    Zhang G; Zeng X; Han L; Wei JA; Huang H
    J Ethnopharmacol; 2010 Mar; 128(2):433-7. PubMed ID: 20083182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats.
    Croci T; Landi M; Gully D; Maffrand JP; Le Fur G; Manara L
    Br J Pharmacol; 1997 Apr; 120(7):1312-8. PubMed ID: 9105707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
    Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
    Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
    Takeuchi M; Lee JD; Shimizu H; Ueda T
    Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
    Ohnishi A; Orita Y; Takagi N; Fujita T; Toyoki T; Ihara Y; Yamamura Y; Inoue T; Tanaka T
    J Pharmacol Exp Ther; 1995 Feb; 272(2):546-51. PubMed ID: 7853167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
    Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.